All schedule II-V controlled substances listed in Minnesota Statutes Sect. 152.02 are required to be reported to the MN PMP.
This list includes additional prescriptions that are scheduled in Minnesota, and not currently federally scheduled such as human growth hormone, pseudoephedrine (reported only when dispensed according to a prescription), and chorionic gonadotropin.
Minnesota has also identified drugs of concern that are required to be reported to the MN PMP. These are gabapentin and all formulations of butalbital.
Why gabapentin?
In 2016 the MN legislature amended statute 152.126 to include gabapentin as a substance required to be reported to the MN PMP. While gabapentin is not a controlled substance federally or in Minnesota, a rise in cases of gabapentin misuse was seen, especially in combination with opioids or other substances to enhance their effects. As a result, MN began requiring the reporting of gabapentin dispensations to better monitor and enable healthcare providers to make safe and informed prescribing decisions. Many states enacted similar legislation, with some even making gabapentin a controlled substance.
